Skip to main content
Top

Breast Cancer Research and Treatment

Issue 3/2006

Content (9 Articles)

Overexpression of caveolin-1 and -2 in cell lines and in human samples of inflammatory breast cancer

Gert G. Van den Eynden, Steven J. Van Laere, Ilse Van der Auwera, Sofia D. Merajver, Eric A. Van Marck, Peter van Dam, Peter B. Vermeulen, Luc Y. Dirix, Kenneth L. van Golen

Clinical Trails

Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan) (AC) response and resistance

Susan Cleator, Anna Tsimelzon, Alan Ashworth, Mitch Dowsett, Timothy Dexter, Trevor Powles, Susan Hilsenbeck, Helen Wong, C. Kent Osborne, Peter O’Connell, Jenny C. Chang

Preclinical study

Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profiling

Steven J. Van Laere, Gert G. Van den Eynden, Ilse Van der Auwera, Melanie Vandenberghe, Peter van Dam, Eric A. Van Marck, Kenneth L. van Golen, Peter B. Vermeulen, Luc Y. Dirix

Preclinical study

The serine-threonine protein phosphatase PPM1D is frequently activated through amplification in aggressive primary breast tumours

Jenita Rauta, Emma-Leena Alarmo, Päivikki Kauraniemi, Ritva Karhu, Tuula Kuukasjärvi, Anne Kallioniemi

Report

Provasopressin expression by breast cancer cells: implications for growth and novel treatment strategies

Brendan P. Keegan, Bonnie L. Akerman, Christel Péqueux, William G. North

Clinical trial

Post-operative arm morbidity and quality of life. Results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer

Anne Fleissig, Lesley J. Fallowfield, Carolyn I. Langridge, Leigh Johnson, Robert G. Newcombe, J. Michael Dixon, Mark Kissin, Robert E. Mansel

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine